Genetic Engineering & Biotechnology News
R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
Patricia F. Dimond, Ph.D.
Recent advancements in the field of next-generation sequencing have resulted in the advent of so-called personal genome machines marketed by Illumina, Life Technologies, and Roche 454. Personal genomics and clinical diagnostics are expected to account for $541 million by 2015 from $15.5 million in 2010, representing a CAGR of 103.5%. ---------
Fast forwarding to the near future and based on the recent past, sequencing instrument companies will continue to develop more user-friendly and cheaper technology, focused on the benchtop and clinical markets. Manufacturers will also continue to form partnerships and make acquisitions that place heavy bets on completely novel, potentially disruptive sequencing technologies.
On a worldwide basis, life science research along with drug discovery and development applications currently comprise the two largest sequencing markets. They together accounted for about $920 million in 2010 and are expected to reach nearly $1.7 billion in 2015 with a compound annual growth of 13%.
By far the largest market opportunity, though, is in emerging applications of personal genomics and clinical diagnostics. ----------------- "
http://www.genengnews.com/insight-and-intelligence/r-d-direction-in-2012-for-sequencing-technologies-is-aimed-at-clinical-medicine/77899529/
tags:
nutrigenomics human nutrition food safety food wars hunger malnutrition poverty genetics nanotechnology robotics kurzweil monsanto dupont pioneer corn genetically modified usda fda eggs beef poultry pork turkey fish shellfish fruits vegetables food borne illness wheat rice oats barley sorghum soybeans alfalfa protein vitamins minerals amino acids fats unidentified growth factors fatty acids genetic engineering climate change food security agribusiness fresh produce desertification nanoliposomes solid lipid nanoparticles nanoemulsions
No comments:
Post a Comment